Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer.

Authors

null

Alison Figueroa Almeda

Stanford University School of Medicine, Stanford, CA

Alison Figueroa Almeda , Anna Hooker , Hojoon Lee , Meredith Mills , Paul Van Hummelen , James M. Ford , Hanlee Ji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 432)

Abstract #

432

Poster Bd #

G21

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

<span>Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.</span>

Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.

First Author: Joseph J Zhao

Poster

2020 ASCO Virtual Scientific Program

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

First Author: Abdul Rafeh Naqash

Poster

2020 ASCO Virtual Scientific Program

Morphologic and molecular analysis of early-onset gastroesophageal adenocarcinomas.

Morphologic and molecular analysis of early-onset gastroesophageal adenocarcinomas.

First Author: Namrata Setia

Poster

2020 Genitourinary Cancers Symposium

Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.

Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.

First Author: Chung-Han Lee